MedPath

Imaging of Prostate Cancer Using Two-dimensional MR Spectroscopy and Diffusion Tensor Imaging

Not Applicable
Withdrawn
Conditions
Prostate Lesions
Registration Number
NCT00611065
Lead Sponsor
University of California, Irvine
Brief Summary

The goal is to develop MR imaging techniques to improve delineation of cancer extent, and to improve differential diagnosis between prostate cancer and benign prostate hyperplasia or other benign diseases.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Male
Target Recruitment
Not specified
Inclusion Criteria
  1. A male older than 21 years of age and under age of 80,
  2. Either a normal healthy volunteer; a patient who has confirmed prostate cancer and decided to receive prostatectomy; or a patient who has persistent elevated PSA higher than 4.0 ng/ml, and with a prior benign biopsy scheduled to receive the second biopsy.
Exclusion Criteria
  1. Unwilling to give informed consent,
  2. Have implanted prosthetic heart valves, pacemaker, neuro-stimulation devices, surgical clips (hemostatic clips) or other metallic implants,
  3. Have engaged in occupations or activities which may cause accidental lodging of ferromagnetic materials, or have imbedded metal fragments from military activities,
  4. Have received orthodontic work involving ferromagnetic materials,
  5. Claustrophobic,
  6. Unable to lie down still for 60 minutes.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
To demonstrate that multi-voxel MR spectroscopy and diffusion tensor imaging can accurately diagnose prostate cancer and benign diseases, also to provide an accurate disease extent.at completion of the study
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Center for Functional Onco-Imaging, University of California

🇺🇸

Irvine, California, United States

© Copyright 2025. All Rights Reserved by MedPath